Erin Bastick, PharmD, RPh
Asthma biologic may reduce oral steroid use
A new trial for AstraZeneca’s benralizumab shows promising results for severe asthma patients.
First generic Strattera for ADHD approved
FDA has approved the first generic versions of Strattera (atomoxetine) for the treatment of attention deficit/hyperactivity disorder.
Pharmaceutical pipeline: Top 4 conditions to watch
Pharmaceutical pipeline: Top 4 conditions to watch
Although drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.
Drugmaker recalls samples of antiplatelet drug
AstraZeneca voluntarily recalls professional samples of its antiplatelet agent. Here's what to do.
Investigational drug appears beneficial in preventing migraines
Lilly's galcanezumab proves successful in three phase 3 migraine studies. Here are the findings.
Combination pack approved for breast cancer treatment
FDA approves ribociclib plus letrozole to treat a subset of advanced breast cancer patients.
Top 5 specialty drug management issues
The 13th edition EMD Serono Specialty Digest outlines top specialty drug management issues health plans face.
How pharma reps impact physician prescribing
A new study led by The University of California researchers and published in JAMA reveals surprising findings.
New therapies show promise in treating diabetes
New therapies show promise in treating diabetes
New updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.
Cannabinoid-based drug pipeline shows promise
Cannabinoid-based drug pipeline shows promise
New treatment indications are under investigation for the use of cannabinoid-based drugs.

Poll

View Results